cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma [version 1; peer review: 3 approved]

cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma [version 1; peer review: 3 approved]

Median survival of patients with glioblastoma (GBM) treated with standard of care which consists of maximal safe resection of the contrast-enhancing portion of the tumor followed by radiation therapy with concomitant adjuvant temozolomide (TMZ) remains 15 months. The tumor microenvironment (TME) is...

Full description

Bibliographic Details
Main Authors: Amy B Heimberger, David M Ashley, Charles David James, Alexander H Stegh, Michael A Curran, Peng Zhang, Justin T Low, Hinda Najem, Akanksha Sanjay Mahajan, Shashwat Tripathi
Format: Article
Language:English
Published: F1000 Research Ltd 2022-09-01
Series:F1000Research
Subjects:
glioblastoma
cGAS-STING
STING Agonist
immune therapies
tumor microenvironment
immune cells
eng
Online Access:https://f1000research.com/articles/11-1010/v1

Internet

https://f1000research.com/articles/11-1010/v1

Similar Items